CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) and Zymeworks (NASDAQ:ZYME – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for CollPlant Biotechnologies and Zymeworks, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
| Zymeworks | 1 | 1 | 12 | 0 | 2.79 |
CollPlant Biotechnologies presently has a consensus price target of $120.00, indicating a potential upside of 2,431.65%. Zymeworks has a consensus price target of $43.25, indicating a potential upside of 63.52%. Given CollPlant Biotechnologies’ higher probable upside, equities analysts plainly believe CollPlant Biotechnologies is more favorable than Zymeworks.
Valuation & Earnings
This table compares CollPlant Biotechnologies and Zymeworks”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CollPlant Biotechnologies | $2.37 million | 3.78 | -$11.49 million | ($13.59) | -0.35 |
| Zymeworks | $105.96 million | 17.23 | -$81.13 million | $0.52 | 50.87 |
CollPlant Biotechnologies has higher earnings, but lower revenue than Zymeworks. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CollPlant Biotechnologies and Zymeworks’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CollPlant Biotechnologies | -678.37% | -298.21% | -167.83% |
| Zymeworks | 16.10% | 22.23% | 7.14% |
Insider and Institutional Ownership
21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Comparatively, 37.7% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
CollPlant Biotechnologies has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
Summary
Zymeworks beats CollPlant Biotechnologies on 11 of the 14 factors compared between the two stocks.
About CollPlant Biotechnologies
CollPlant Biotechnologies is an Israel-based regenerative medicine company developing products and technologies based on recombinant human collagen (rhCollagen). Its proprietary production process uses genetically engineered plants to produce human collagen, offering an alternative to collagen sourced from animals or human tissue. The company’s rhCollagen platform is intended for applications including tissue repair, 3D bioprinting and medical aesthetics. Its development work includes bioinks and other collagen-based materials designed for use in regenerative medicine and tissue engineering.
About Zymeworks
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
